Shaji K. Kumar, MD, on How CAR T-Cell Therapies Are Changing the Therapeutic Landscape in Multiple Myeloma

Posted: Wednesday, May 10, 2023

Shaji K. Kumar, MD, of the Mayo Clinic, Rochester, Minnesota, discusses how two chimeric antigen receptor (CAR) T-cell therapies—idecabtagene vicleucel and ciltacabtagene autoleucel—are changing the therapeutic landscape in the clinic for patients with multiple myeloma. He briefly explores both the benefits and adverse events associated with these immunotherapies.

---